In this edition of our newsletter, we explore Consulting 2026

In this edition of our newsletter, we explore Consulting 2026: Innovation, AI and the Human Advantage — and what this shift means for how Life Science organisations work with expertise and partners.

As innovation and AI reshape the industry, Pharma and Medical Device companies increasingly rely on consulting and outsourcing to access specialised competence, increase flexibility and support transformation. Functions such as quality assurance, regulatory affairs, pharmacovigilance and marketing compliance are becoming integral parts of future-ready operating models.

In a highly regulated environment, where patient safety and compliance are non-negotiable, it is the combination of technology and human expertise that creates real value. The right consulting approach can accelerate innovation, manage risk and help organisations stay ahead.

👉 Read more here